Immatics N.V. IMTX 深 滬
已收盤 02-06 16:00:00 美东时间
9.63
+1.060
+12.37%
華盛通- 最 高9.75
- 今 開8.86
- 成交量 48.51万股
- 最 低 8.71
- 昨 收 8.57
- 總市值 12.91亿
- 52周最高 12.41
- 市盈率 靜 62.49
- 換手率 0.36%
- 52周最低 3.30
- 委 比 80.74%
- 總股本 1.34亿
- 歷史最高 18.42
- 量 比 1.21
- 振 幅 12.14%
- 歷史最低 3.30
- 每 手 1
- 風險率 2.32%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Immatics Unveils IMA203CD8 Phase 1a Findings Demonstrating Durable Responses And Tumor-Agnostic Potential In PRAME-Expressing Cancers
IMA203CD8 is a second-generation PRAME cell therapy with enhanced pharmacology in ongoing Phase 1a dose escalationManageable tolerability across all dose levelsEncouraging early clinical anti-tumor activity in advanced
2025-12-11 20:11
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Praxis Precision Medicine (NASDAQ:PRAX) shares moved upwards by 33.6% ...
2025-12-06 01:05
Immatics To Raise $125M Through Sale of 12.5M Shares at $10 Each
Immatics N.V. (NASDAQ:IMTX, "Immatics" or the "Company"))), a clinical-stage biopharmaceutical company and the global leader in precision targeting of PRAME, announced today that it has agreed to sell 12,500,000 ordinary
2025-12-05 19:05
美股大行评级 | 摩根大通上调百度至"超配"，目标价升至188美元！Navan获多家机构首予"买入"评级，目标价最高30美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从4美元升至9美元；BTIG：维持Cullinan Therapeutics"买入"评级，目标价从32美元升至38美元
2025-11-25 10:27
Chardan Capital Maintains Buy on Immatics, Maintains $25 Price Target
Chardan Capital analyst Geulah Livshits maintains Immatics (NASDAQ:IMTX) with a Buy and maintains $25 price target.
2025-11-25 00:02
美股大行评级 | 高盛上调百度、美敦力、晶科能源等多只个股目标价；家得宝遭9家机构下调目标价；
今日重点评级关注：富国银行：维持Annexon"超配"评级，目标价从14美元升至27美元；瑞穗：上调Relmada Therapeutics评级至"跑赢大市"，目标价从1美元升至10美元
2025-11-20 10:28
美股大行评级 | Stifel上调英伟达目标价升至250美元；大摩上调哔哩哔哩目标价升至27美元；NICE遭多家机构下调目标价
今日重点评级关注：Oppenheimer：维持Olema Pharmaceuticals"跑赢大市"评级，目标价从22美元升至45美元；Bernstein：维持Atlassian"跑赢大市"评级，目标价从290美元升至304美元
2025-11-19 11:01
Immatics shares are trading higher after the company announced updated Phase 1a dose escalation data from both product candidates in its TCR Bispecifics pipeline
Immatics shares are trading higher after the company announced updated Phase 1a...
2025-11-13 02:13
Immatics Appoints Amie Krause as Chief People Officer
Houston, Texas and Tuebingen, Germany, October 27, 2025 – Immatics N.V. (NASDAQ...
2025-10-27 19:00
Immatics Presents Updated Data From 16 Patients With Metastatic Uveal Melanoma Treated With Anzu-Cel PRAME Cell Therapy At ESMO 2025 Presidential Symposium
One-time infusion of anzu-cel (anzutresgene autoleucel, IMA203) PRAME cell therapy in 16 patients with metastatic uveal melanoma in the ongoing Phase 1b trial continues to show strong clinical benefit with more matureOne-time infusion of anzu-cel (anzutresgene autoleucel, IMA203) PRAME cell therapy in 16 patients with metastatic uveal melanoma in the ongoing Phase 1b trial continues to sho
2025-10-20 22:32
